JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Omeros Corp

Closed

SectorHealthcare

7.65 -0.78

Overview

Share price change

24h

Current

Min

7.59

Max

7.91

Key metrics

By Trading Economics

Income

8M

-25M

Profit margin

-8,121.359

Employees

202

EBITDA

9.3M

-26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+71.63% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

284M

561M

Previous open

8.43

Previous close

7.65

News Sentiment

By Acuity

18%

82%

29 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Omeros Corp Chart

Past performance is not a reliable indicator of future results.

Related News

15 Oct 2025, 15:36 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 Oct 2025, 13:27 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15 Oct 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 Oct 2025, 12:32 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 Oct 2025, 12:32 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 Oct 2025, 12:32 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Peer Comparison

Price change

Omeros Corp Forecast

Price Target

By TipRanks

71.63% upside

12 Months Forecast

Average 13.13 USD  71.63%

High 20 USD

Low 6.269 USD

Based on 3 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.265 / 7.49Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

29 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat